Schonfeld Strategic Advisors LLC Buys New Stake in Inhibrx, Inc. (NASDAQ:INBX)

Schonfeld Strategic Advisors LLC bought a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 144,178 shares of the company's stock, valued at approximately $2,220,000. Schonfeld Strategic Advisors LLC owned about 1.00% of Inhibrx as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. acquired a new position in shares of Inhibrx in the fourth quarter worth $28,000. Natixis purchased a new stake in Inhibrx during the 4th quarter worth about $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in Inhibrx during the 4th quarter worth about $47,000. New York State Common Retirement Fund purchased a new stake in Inhibrx during the 4th quarter worth about $53,000. Finally, Corebridge Financial Inc. purchased a new stake in Inhibrx during the 4th quarter worth about $89,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Inhibrx Price Performance

NASDAQ INBX traded down $0.08 during trading hours on Friday, hitting $11.18. 77,931 shares of the company were exchanged, compared to its average volume of 186,181. The company has a 50 day moving average of $12.82 and a two-hundred day moving average of $13.78. Inhibrx, Inc. has a 52-week low of $10.80 and a 52-week high of $34.73.

Inhibrx (NASDAQ:INBX - Get Free Report) last posted its earnings results on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The company had revenue of $0.10 million during the quarter. Analysts forecast that Inhibrx, Inc. will post 104.88 EPS for the current fiscal year.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.